CJC-1295
Encyclopedia
CJC-1295 is a tetrasubstituted 30-amino acid
peptide hormone
, primarily functioning as a growth hormone releasing hormone
(GHRH) analog
. It was invented by ConjuChem
, a Canadian biotechnology company.
One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin
, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug's marketing stalled when three of the trial's patients suffered a myocardial infarction
.
Amino acid
Amino acids are molecules containing an amine group, a carboxylic acid group and a side-chain that varies between different amino acids. The key elements of an amino acid are carbon, hydrogen, oxygen, and nitrogen...
peptide hormone
Peptide hormone
Peptide hormones are a class of peptides that are secreted into the blood stream and have endocrine functions in living animals.Like other proteins, peptide hormones are synthesized in cells from amino acids according to an mRNA template, which is itself synthesized from a DNA template inside the...
, primarily functioning as a growth hormone releasing hormone
Growth hormone releasing hormone
Growth-hormone-releasing hormone , also known as growth-hormone-releasing factor , somatoliberin or somatocrinin, is a releasing hormone for growth hormone...
(GHRH) analog
Functional analog
Functional analogs , are compounds that have similar physical, chemical, biochemical, or pharmacological properties. An example of a functional analog is morphine and heroin. Functional analogs are not necessarily also structural analogs with a similar chemical structure...
. It was invented by ConjuChem
ConjuChem
ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Canada and employs 45 people, 90% of whom are in research and development....
, a Canadian biotechnology company.
One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin
Serum albumin
Serum albumin, often referred to simply as albumin is a protein that in humans is encoded by the ALB gene.Serum albumin is the most abundant plasma protein in mammals. Albumin is essential for maintaining the osmotic pressure needed for proper distribution of body fluids between intravascular...
, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.
ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug's marketing stalled when three of the trial's patients suffered a myocardial infarction
Myocardial infarction
Myocardial infarction or acute myocardial infarction , commonly known as a heart attack, results from the interruption of blood supply to a part of the heart, causing heart cells to die...
.